Chardan Capital Reaffirms Their Buy Rating on Arrowhead Research (ARWR)


Chardan Capital analyst Keay Nakae reiterated a Buy rating on Arrowhead Research (ARWR) on December 12 and set a price target of $24.50. The company’s shares closed on Friday at $14.32.

According to TipRanks.com, Nakae is ranked 0 out of 5 stars with an average return of -10.7% and a 28.0% success rate. Nakae covers the Healthcare sector, focusing on stocks such as Arbutus Biopharma Corporation, Arcturus Therapeutics Ltd, and Dicerna Pharma.

Arrowhead Research has an analyst consensus of Strong Buy, with a price target consensus of $24.50, which is a 71.1% upside from current levels. In a report issued on December 11, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $24 price target.

.

See today’s analyst top recommended stocks >>

Based on Arrowhead Research’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $10.76 million. In comparison, last year the company had a GAAP net loss of $10.73 million.

Based on the recent corporate insider activity of 25 insiders, corporate insider sentiment is negative on the stock. Most recently, in October 2018, Peter Brian Leone, the VP, Strategic Bus. Initiatives of ARWR sold 131,137 shares for a total of $1,769,038.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Arrowhead Pharmaceuticals, Inc. operates as a biopharmaceutical company, which develops medicines that treat diseases. The company was founded by R. Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts